[New endocrine treatments prolong survival of patients with castration-resistant prostate cancer].
Prostate cancer that progresses despite castrate levels of serum testosterone is defined as castration-resistant prostate cancer (CRPC). Molecular investigations of the disease have established that progression of CRPC remains driven by androgen receptor signalling and that CRPC continues to respond to hormonal manipulation. Recently, new endocrine treatments including an androgen receptor signalling inhibitor and a testosterone synthesis inhibitor have been approved for treatment of CRPC. We review the pivotal phase 3 trials and discuss their implications for future treatment of CRPC.
Urologisk Klinik, Rigshospitalet, Blegdamsvej 9, 2100 København Ø. klausbrasso@hotmail.com
Klaus
K
Brasso
Frederik Birkebæk
FB
Thomsen
Kasper Drimer
KD
Berg
Martin Andreas
MA
Røder
Peter
P
Iversen
D000726:Androgen Antagonists / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D000736:Androstenes / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D001549:Benzamides; D006801:Humans; D008297:Male; D009570:Nitriles; D010669:Phenylthiohydantoin / Q000009:adverse effects / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000401:mortality; D013254:Steroid 17-alpha-Hydroxylase / Q000037:antagonists & inhibitors; D015996:Survival Rate
D000726:Androgen Antagonists; D000736:Androstenes; D018931:Antineoplastic Agents, Hormonal; D001549:Benzamides; D009570:Nitriles; D010669:Phenylthiohydantoin; C540278:enzalutamide; D013254:Steroid 17-alpha-Hydroxylase; C089740:abiraterone